CYP3A4 and fungal infectious disease: In clinical practice, as a therapeutic strategy for patients with cancer, OSIM is administered in conjunction with CYP3A inhibitors to decrease the incidence of invasive fungal infections (Gerber et al., 2020; Pagano et al., 2012; Vishwanathan et al., 2018).